ProMIS Neurosciences, Inc. – NASDAQ:PMN
ProMIS Neurosciences stock price today
ProMIS Neurosciences stock price monthly change
ProMIS Neurosciences stock price quarterly change
ProMIS Neurosciences stock price yearly change
ProMIS Neurosciences key metrics
Market Cap | 30.07M |
Enterprise value | N/A |
P/E | -2.11 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 9225.17 |
Price/Book | -28.33 |
PEG ratio | 0.02 |
EPS | -0.84 |
Revenue | N/A |
EBITDA | -12.80M |
Income | -11.88M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -473610.95% |
Oper. margin | -649766.83% |
Gross margin | 0% |
EBIT margin | -649766.83% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeProMIS Neurosciences stock price history
ProMIS Neurosciences stock forecast
ProMIS Neurosciences financial statements
| Jun 2023 | 0 | -2.31M | |
|---|---|---|---|
| Sep 2023 | 0 | -2.36M | |
| Dec 2023 | 6.27K | -3.58M | -57058.63% |
| Mar 2024 | 0 | -3.63M |
| 2025 | 1.12B | -33.09M | -2.93% |
|---|---|---|---|
| 2026 | 0 | -45.22M | |
| 2027 | 0 | -4.26M | |
| 2028 | 0 | 6.72M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 1984535 | 11.57M | 583.35% |
|---|---|---|---|
| Sep 2023 | 24279868 | 13.38M | 55.11% |
| Dec 2023 | 18044958 | 12.38M | 68.65% |
| Mar 2024 | 4806314 | 3.58M | 74.57% |
| Jun 2023 | -2.14M | 0 | 0 |
|---|---|---|---|
| Sep 2023 | -2.37M | -76.78K | 18.33M |
| Dec 2023 | -3.63M | -1.33K | -748.01K |
| Mar 2024 | -10.29M | 0 | 190.27K |
ProMIS Neurosciences alternative data
| Aug 2023 | 6 |
|---|---|
| Sep 2023 | 6 |
| Oct 2023 | 6 |
| Nov 2023 | 6 |
| Dec 2023 | 6 |
| Jan 2024 | 6 |
| Feb 2024 | 6 |
| Mar 2024 | 6 |
| Apr 2024 | 6 |
| May 2024 | 6 |
| Jun 2024 | 6 |
| Jul 2024 | 6 |
ProMIS Neurosciences other data
| Period | Buy | Sel |
|---|---|---|
| Jul 2024 | 6511624 | 0 |
| Aug 2024 | 10000 | 0 |
| Sep 2024 | 293223 | 0 |
-
What's the price of ProMIS Neurosciences stock today?
One share of ProMIS Neurosciences stock can currently be purchased for approximately $0.57.
-
When is ProMIS Neurosciences's next earnings date?
Unfortunately, ProMIS Neurosciences's (PMN) next earnings date is currently unknown.
-
Does ProMIS Neurosciences pay dividends?
No, ProMIS Neurosciences does not pay dividends.
-
How much money does ProMIS Neurosciences make?
ProMIS Neurosciences has a market capitalization of 30.07M.
-
What is ProMIS Neurosciences's stock symbol?
ProMIS Neurosciences, Inc. is traded on the NASDAQ under the ticker symbol "PMN".
-
What is ProMIS Neurosciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of ProMIS Neurosciences?
Shares of ProMIS Neurosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does ProMIS Neurosciences have?
As Jul 2024, ProMIS Neurosciences employs 6 workers.
-
When ProMIS Neurosciences went public?
ProMIS Neurosciences, Inc. is publicly traded company for more then 18 years since IPO on 10 Jan 2007.
-
What is ProMIS Neurosciences's official website?
The official website for ProMIS Neurosciences is promisneurosciences.com.
-
Where are ProMIS Neurosciences's headquarters?
ProMIS Neurosciences is headquartered at 1920 Yonge Street, Toronto, ON.
-
How can i contact ProMIS Neurosciences?
ProMIS Neurosciences's mailing address is 1920 Yonge Street, Toronto, ON and company can be reached via phone at +41 68476898.
ProMIS Neurosciences company profile:
ProMIS Neurosciences, Inc.
promisneurosciences.comNASDAQ
6
Biotechnology
Healthcare
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Toronto, ON M4S 3E2
CIK: 0001374339
ISIN: CA74346M4065
CUSIP: 74346M406
